Abstract
High-risk spinal surgeries such as intramedullary spinal cord tumor resection and complex deformity correction may result in spinal cord injury (SCI). Currently, intravenous (IV) high-dose methylprednisolone (MP) is the only pharmacological treatment for SCI. However, its use has been controversial, in part due to the high rate of systemic adverse effects. We hypothesized that prophylactic intrathecal (IT) MP would result in increased local bioavailabilty at the injury site resulting in better motor recovery while minimizing adverse effects associated with systemic MP administration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
